Jun 08, 2021

Chugai Selected as Digital Transformation Stock (DX Stock) 2021

  • DX Stock 2021 is jointly selected by METI and TSE to accelerate the digital transformation of Japanese companies
  • Chugai is the only company selected for the second consecutive year as DX Stock in the pharmaceutical industry

TOKYO, June 8, 2021 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that it has been selected as one of the “Digital Transformation Stocks (DX Stocks) 2021” by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE). From among TSE-listed companies, “DX Stocks” are designated to those companies, in each industrial category, that have established internal systems to promote digital transformation (DX) leading to increased corporate value, and have outstanding achievements in digital utilization. Chugai is selected for the second consecutive year as DX Stock.

28 TSE-listed companies were selected in consideration of contribution to corporate value, and capability of DX realization. Under the positive commitment of top management, clear digital vision and investment policy, Chugai’s efforts to reform the drug discovery development process using AI etc., strengthen human resources and culture, and provide new value to patients were highly evaluated.

In order to realize its vision of becoming a top innovator in the healthcare industry, Chugai formulated a new growth strategy “TOP I 2030,” which is consisted of two pillars of “global first-class drug discovery” and a “futuristic business model.” DX is positioned as one of the key drivers to achieve the vision. In accelerating DX, Chugai is committed to transforming its business and providing healthcare solutions that will change society through three basic strategies of CHUGAI DIGITAL VISION 2030: 1) strengthening digital platforms, 2) optimize all value chains, and 3) digital transformation for drug discovery and development.




CHUGAI DIGITAL official note (in Japanese only)


DX Stock 2021 logo


  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Tomoko Shimizu
  • Tel: +81-3-3273-0881
  • E-mail: pr@chugai-pharm.co.jp
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Takayuki Sakurai
  • Tel: +81-3-3273-0554
  • E-mail: ir@chugai-pharm.co.jp
  • Like
  • Post
  • LINE it!
  • E-mail
Back to top